Sign in
4

Changes in Ownership

IRulya Therapeutics Inc. Filed Acc 0001209191-21-044027

COO & Chief Financial Officer sold 20,000 shares at an average $54.15 ($1,083,074)

  • COO & Chief Financial Officer acquired 50,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

LOWE CHRISTOPHER P. · COO & Chief Financial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2021-06-28 Exercise or conversion : show line 1 in the form +20,000 $2.23 $44,600 20,000 D
2021-06-28 Sale : show line 2 in the form −7,724 $53.39 $412,384 12,276 D
2021-06-28 Sale : show line 3 in the form −7,079 $54.13 $383,186 5,197 D
2021-06-28 Sale : show line 4 in the form −4,153 $55.11 $228,872 1,044 D
2021-06-28 Sale : show line 5 in the form −1,044 $56.16 $58,631 0 D
2021-06-30 Exercise or conversion : show line 6 in the form +30,000 $2.23 $66,900 30,000 D
Open-market sales · 20,000 sh · avg $54.15 · $1,083,074

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2021-06-28 Exercise or conversion : show line 7 in the form Stock Option (right to buy) −20,000 215,594 D
2021-06-30 Exercise or conversion : show line 8 in the form Stock Option (right to buy) −30,000 185,294 D
Loading xslF345X03/doc4.xml…